1 Quarter 2019 - Eckert & Ziegler Strahlen- und Medizintechnik AG · 2019-05-07 · –New Projects...
Transcript of 1 Quarter 2019 - Eckert & Ziegler Strahlen- und Medizintechnik AG · 2019-05-07 · –New Projects...
1
1st Quarter 2019
7 May 2019
Dr. Andreas Eckert
CEO
2
Berlin
Medical Devices (RADIATION THERAPY)
Implantats
Applicators
Devices
Raw materials/
API
Projects/
API
Pharmaceuticals (RADIOPHARMA)
Devices
Globally Positioned
Niche Player in Isotope Market
Industrial Components
(ISOTOPE PRODUCTS)
Products
Services
Trade
Disposal
A strong start in Q01-2019 with a total revenues of 44 Mio. Euro. Calendar year
2018 closed with revenues of 169 Mio. Euro, incl. discontinued operations.
27 Mio. EUR
63%
6 Mio. EUR
15%
10 Mio. EUR
23%
Slides only for illustration – the spoken word shall be binding
800 Employees (Headcounts)
19 Sites Worldwide
3
Results in Q1-2019 (Mio. EUR)
Revenues 43,5
Net Income 5,8
Slides only for illustration – the spoken word shall be binding
43%
46%
9%
2%
EUROPE AMERICA ASIA MIDDLE EAST & AFRICA
2%
Past Years Revenues Outlook
in M
io. E
UR
4
incl. discontinued and continued operations
A total organic growth of 18% in 2018
0,13 1 2 4 6 6 8 10
24
33 31 29
36
42
50 54
71
101
111 116
120 117
127
140 138
145
169
0
20
40
60
80
100
120
140
160
180
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Slides only for illustration – the spoken word shall be binding
Revenues per Segment
Q01-2019 vs. Q01-2018
5 Slides only for illustration – the spoken word shall be binding
Total Revenues of 43,5 Mio. EUR in Q01-2019 vs. 35,7 Mio. EUR in Q01-2018.
And a total organic growth of 19% in Q01-2019.
incl. discontinued and continued operations
0
5
10
15
20
25
30
Isotope Products Radiation Therapy Radiopharma
Q01-2018 22 7 7
Q01-2019 27 6 10
In M
io. E
UR
Revenue Growth all Segments
in Q01-2019, in Mio. EUR
6 Slides only for illustration – the spoken word shall be binding
35,7
+ 4,7 - 0,3
+ 3,4
43,5
0
5
10
15
20
25
30
35
40
45
Revenues Q01-2018 Isotope Products Strahlentherapie Radiopharma Revenues Q01-2019
Isotope Products Revenue
Growth Q01-2019, in Mio. EUR
7 Slides only for illustration – the spoken word shall be binding
High Demand in
Energy Sector 22,4
+ 3,6
+ 1,1
27,2
20
21
22
23
24
25
26
27
28
Revenues Q01-2018 Organic Growth Exchange Rate Effects Revenues Q01-2019
6,6
+ 3,0
+ 0,4
10,0
5
6
7
8
9
10
11
Revenues Q01-2018 Organic Growtth Exchange Rate Effects Revenues Q01-2019
Radiopharma Revenue Growth
Q01-2019, in Mio. EUR
8 Slides only for illustration – the spoken word shall be binding
Pharmaceutical
Radioisotope
6,7
- 0,1 + 0,1
- 0,4
6,4
5
5
5
6
6
6
6
6
7
7
7
Revenues Q01-2018 Organic Growth Exchange Rate Effects M&A and Divesture Revenues Q01-2019
Radiation Therapy Revenue
Growth Q01-2019, in Mio. EUR
9 Slides only for illustration – the spoken word shall be binding
WOMED
lower revenues
in Q01-2019 vs.
Q01-2018
10 Slides only for illustration – the spoken word shall be binding
Q01-2019
Net Income – Distribution and Growth
Net Income in Q01-2019 vs.
Q01-2018 in Mio. EUR
11
Total Net Income of 5,8 Mio. EUR in Q01-2019 vs. 2,3 Mio. in Q01-2018
Slides only for illustration – the spoken word shall be binding
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
Isotope Products Radiation Therapy Radiopharma
Q01-2018 0,9 0,4 1,3
Q01-2019 3,0 0,4 2,4
In M
io. E
UR
Net Income Distribution
by Segment, Q01-2019
12
5,8 Mio. EUR Net Income
Isotope
Products
Radio-
pharma
Radiation
Therapy
3,0 2,4 0,4
Split in Mio. EUR without Holding
Slides only for illustration – the spoken word shall be binding
53%
6%
41%
Isotope Products Radiation Therapy Radiopharma
Revenue Distribution by
Segment, Q01-2019
13 Slides only for illustration – the spoken word shall be binding
43,5 Mio. EUR Revenues
Isotope
Products
Radio-
pharma
Radiation
Therapy
27,2 10,0 6,4
Split in Mio. EUR without Holding
62% 15%
23%
Isotope Products Radiation Therapy Radiopharma
Net Income Growth all Segments
in Q01-2019, in Mio. EUR
14 Slides only for illustration – the spoken word shall be binding
2,3
+ 2,1
- 0,1
+ 1,1
+ 0,3
5,8
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
Net Income Q01-2018 Isotope Products Radiation Therapy Radiopharma Holding Net Income Q01-2019
15 Slides only for illustration – the spoken word shall be binding
Q01-2019
Cashflow and Balance Sheet
Balance Sheet in 2018
in Mio. EUR
16
• Cash at Hand 60 Mio. EUR
• Debt Free
• Equity Ratio 52%
Slides only for illustration – the spoken word shall be binding
Cash 60 Equity 125
Recievables 28 Minority Interests 6
Inventory 30 Loans 0
Intangible Assets 72 Accruals/Provisions 66
Fixed Assets 37 Other Short Term Payables 30
Others 26 Other Long Term Payables 26
Total Activ 253 Total Passiv 253
54,2
7,7
-1,4 -0,7
0,3
60,1
30,0
35,0
40,0
45,0
50,0
55,0
60,0
65,0
Cash at 31.12.2018 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Cash at 31.03.2019
Cashflow in Q01-2019
in Mio. EUR
17 Slides only for illustration – the spoken word shall be binding
EBITDA: 11,6 Mio. EUR
18 Slides only for illustration – the spoken word shall be binding
5 YEAR PERSPECTIVE
19
Mergers and Acquisitions,
Cooperations
• 2014
– Acquisition of Brazilian Isotope Specialist REM
– Accreditation Gallium Generator/ API
– New Projects & Business Activities in Therapy Segment
• 2015 – Sale of US-Seed Business to Theragenics
– Closing of Oxford/ (US)
– Closing of French Sales Accessories Unit
– Lucrative Sales of OPS to IPSEN
• 2016 – Acquisition of Belgian Brachytherapie Unit
– Acquisition of Brazilian Transports Specialist
– Cooperation Contract with CURASIGHT
– FDA-Approval for NETSPOT/ (API of EZAG)
• 2017 – Sale of Zyklotron Business to Alliance Medical
– Acquisition of Gamma-Service Group, Leipzig
• 2018 Acquisition of WOMED
Merger BEBIG S.A. und EZAG AG
Slides only for illustration – the spoken word shall be binding
Profitability (Net Income/ EPS)
of the Past 5 Years
6,8
10,7
9,6
14,7
16,1
1,28 €
2,03 €1,81 €
2,78 €
3,12 €
0,0
2,0
4,0
6,0
8,0
10,0
12,0
14,0
16,0
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
2014 2015 2016 2017 2018
Mio. EUR EUR/Aktie
20 Slides only for illustration – the spoken word shall be binding
„Verdauung“
Industry
& RI
Basis: 5,2 Mio. shares
Planned Profitability in 2019
(Net Income/ EPS)
21 Slides only for illustration – the spoken word shall be binding
Basis: 5,1 Mio. shares
6,8
10,79,6
14,7
16,1
18,1
1,28 €
2,03 € 1,81 €
2,78 €
3,12 €
3,50 €
5,0
7,0
9,0
11,0
13,0
15,0
17,0
19,0
0,50
1,00
1,50
2,00
2,50
3,00
3,50
4,00
2014 2015 2016 2017 2018 2019 Budget
Mio. EUR EUR/Aktie
In 2019, the Group expects an EPS of 3,50 Euro.
Stock and Dividend,
In EUR/Stock
22 Slides only for illustration – the spoken word shall be binding
0,60 0,60 0,600,66
0,8
1,2
0,50
0,60
0,70
0,80
0,90
1,00
1,10
1,20
0
10
20
30
40
50
60
70
80
90
100
2014 2015 2016 2017 2018 2019
Dividende in EUR / Aktie EUR/Aktie
Cashflow Outlook,
in Mio. EUR
23 Slides only for illustration – the spoken word shall be binding
+10 mm EUR for
treasury shares
2014 2015 2016 2017 2018 Q01-2019
Zahlungsmittel 22 31 37 58 54 60
Darlehen 19 16 12 2 0 0
Nettoliquidität 3 15 25 56 54 60
0
10
20
30
40
50
60
0
10
20
30
40
50
60
In M
io. E
UR
Financial Calendar / IR-Contact
IR-Kontakt
Eckert & Ziegler AG
Karolin Riehle
Investor Relations & PR
Robert-Rössle-Str. 10
D-13125 Berlin
Tel. +49 30 94 10 84-138
Fax +49 30 94 10 84-112
www.ezag.de
ISIN DE0005659700
Reuters EUZ.DE
24 Slides only for illustration – the spoken word shall be binding
07.05.2019 Quarterly Report I
15.05.2019 Spring Conference in Frankfurt
29.05.2019 Annual General Meeting in Berlin
13.08.2019 Quarterly Report II
12.11.2019 Quarterly Report III
Nov. 2019 German Equity Forum in Frankfurt